Other Clinical Trial - Low GI Diet in Children & Adolescents With ALL

Status Active, not recruiting

Clinical Trial Summary

The study aims to determine the feasibility of a 6-month low glycemic dietary intervention in children and adolescents undergoing treatment for acute lymphoblastic leukemia.

Clinical Trial Description

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy with survival exceeding 90%. However, treatment-related toxicity remains a clinical challenge during and after treatment. Evidence-based, nutritional interventions may minimize the development of nutrition-related toxicities, such as bone morbidities, hypertriglyceridemia, and obesity. To date, no effective interventions are available to prevent nutrition-related morbidities in children with ALL. Clinical studies evaluating the glycemic indices in other pediatric conditions have been encouraging. It is plausible that reducing the glycemic indices of diets during cancer treatment may have a profound clinical effect in this vulnerable pediatric population. Prior to the design and implementation of randomized, controlled trials, epidemiological data describing the Glycemic Index (GI) and Glycemic Load (GL) and the association with clinically important outcomes is needed. Additionally, the feasibility of a dietary intervention must also be explored within the setting of pediatric cancer. This study aims to determine the feasibility, measured by compliance to a low-GI diet, of a 6-month low glycemic dietary intervention in children and adolescents undergoing treatment for ALL. The proposed work will be used for the design and implementation of a multi-center nutritional intervention aimed at improving dietary intake during treatment and its effect on clinically important outcomes. Importantly, the information will be used to drive the formation of evidence-based nutritional guidelines for children with cancer, which will expand into the emerging field of individualized medicine for patients with cancer. ;

Study Design

Related Conditions & MeSH terms

Acute Lymphoblastic Leukemia, Pediatric
Leukemia
Leukemia, Lymphoid
Obesity, Pediatric
Pediatric Obesity
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT03157323
Study type	Interventional
Source	Columbia University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	June 1, 2017
Completion date	June 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03676504` - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR	Phase 1/Phase 2
Enrolling by invitation	`NCT05622682` - Vaccine Immune Recovery After Leukemia
Not yet recruiting	`NCT05029531` - Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)	Phase 3
Not yet recruiting	`NCT06107478` - Parental Perception of Their Child's Emotional Quality of Life in Paediatric Oncology Before and After "Magic Massages"
Recruiting	`NCT04049383` - CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL	Phase 1
Active, not recruiting	`NCT04472286` - Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
Completed	`NCT05973032` - MRD Detection by NGS in Pediatric B-ALL
Completed	`NCT05032716` - EFFECT OF TREADMILL TRAINING ON BALANCE AFTER CHEMOTHERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA	N/A
Not yet recruiting	`NCT05809284` - Determining the Mechanisms of Loss of CAR T Cell Persistence
Recruiting	`NCT03035344` - Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL)	N/A
Terminated	`NCT03705507` - International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia	Phase 1/Phase 2
Recruiting	`NCT04325841` - Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children	Phase 2
Active, not recruiting	`NCT03020030` - Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents	Phase 3
Not yet recruiting	`NCT06257394` - Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea	Phase 2
Recruiting	`NCT04996160` - Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)	Phase 1
Recruiting	`NCT03643276` - Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017	Phase 3
Active, not recruiting	`NCT04088864` - CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies	Phase 1
Completed	`NCT04770922` - Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia
Not yet recruiting	`NCT04228393` - The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China	Phase 2/Phase 3
Recruiting	`NCT04400071` - Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Low GI Diet in Children and Adolescents With ALL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms